genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2012
Santhera Pharmaceuticals
News
Santhera Regains Global Rights to Parkinson Disease Drug Fipamezole from Ipsen
Cancer
BioLineRx Nabs Rights to Santhera’s Preclinical MC-4R Cachexia Program
News
Ipsen Acquires Santhera’s Parkinson Drug for €13M Up Front
News
Santhera Shares Drop 35% as Friedreich Ataxia Drug Fails in Phase III
News
Santhera Implements Named Patient Program for Friedrich’s Ataxia Drug in Europe and Switzerland
News
Biovail Pays Santhera $8M Up Front for North American Rights to Parkinson’s Therapy
News
Santhera’s Friedreich’s Ataxia Drug Fails in U.S. Phase III Trial
News
Santhera and University of Basel Join NMD Network
Scroll Up